Literature DB >> 28087475

Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.

Won-Tak Choi1, Rageshree Ramachandran2, Sanjay Kakar2.   

Abstract

Well-differentiated hepatocellular carcinoma (HCC) shares overlapping histological features with benign hepatocellular lesions, including hepatocellular adenoma and focal nodular hyperplasia in non-cirrhotic liver, and with high-grade dysplastic nodule in cirrhotic liver. Several metastatic tumors, such as neuroendocrine tumor, renal cell carcinoma, adrenocortical carcinoma, melanoma, and epithelioid angiomyolipoma, can be indistinguishable from HCC on histologic grounds. Since this distinction has important therapeutic implications, judicious use of immunohistochemical markers plays an important role in establishing an accurate diagnosis, especially when limited material of tumor is available on cell block or a small core biopsy. This review describes commonly used immunohistochemical markers used in the diagnosis of HCC, highlighting advantages and disadvantages of each marker, and suggests appropriate immunohistochemical panels for specific clinicopathologic situations.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Focal nodular hyperplasia; Hepatocellular adenoma; Hepatocellular carcinoma; Immunohistochemistry; Well-differentiated hepatocellular lesion

Mesh:

Substances:

Year:  2017        PMID: 28087475     DOI: 10.1016/j.humpath.2016.12.025

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Hepatocellular nodules in vascular liver diseases.

Authors:  Christine Sempoux; Charles Balabaud; Valérie Paradis; Paulette Bioulac-Sage
Journal:  Virchows Arch       Date:  2018-05-26       Impact factor: 4.064

2.  Malignant potential of epithelioid angiomyolipomas of the liver: A case report and comprehensive review of the literature.

Authors:  Zoe Garoufalia; Nikolaos Machairas; Ioannis D Kostakis; Aliki Liakea; Petros Tsaparas; George Liapis; Georgios C Sotiropoulos
Journal:  Mol Clin Oncol       Date:  2018-06-15

Review 3.  Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.

Authors:  Taek Chung; Young Nyun Park
Journal:  Front Med (Lausanne)       Date:  2022-03-31

Review 4.  Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site.

Authors:  Janick Selves; Elodie Long-Mira; Marie-Christine Mathieu; Philippe Rochaix; Marius Ilié
Journal:  Cancers (Basel)       Date:  2018-04-05       Impact factor: 6.639

5.  Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases.

Authors:  Dingbao Chen; Zhao Li; Qiujing Song; Lihua Qian; Batubaiyin Xie; Jiye Zhu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

6.  MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2.

Authors:  Ling-Xiang Yu; Bo-Lun Zhang; Mu-Yi Yang; Hu Liu; Chao-Hui Xiao; Shao-Geng Zhang; Rong Liu
Journal:  Onco Targets Ther       Date:  2019-07-15       Impact factor: 4.147

7.  Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma.

Authors:  Na Sun; Yi-Te Lee; Minhyung Kim; Jasmine J Wang; Ceng Zhang; Pai-Chi Teng; Dongping Qi; Ryan Y Zhang; Benjamin V Tran; Yue Tung Lee; Jinglei Ye; Juvelyn Palomique; Nicholas N Nissen; Steven-Huy B Han; Saeed Sadeghi; Richard S Finn; Sammy Saab; Ronald W Busuttil; Edwin M Posadas; Li Liang; Renjun Pei; Ju Dong Yang; Sungyong You; Vatche G Agopian; Hsian-Rong Tseng; Yazhen Zhu
Journal:  Adv Mater Technol       Date:  2021-04-09

Review 8.  Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors.

Authors:  Yoshihisa Takahashi; Erdenetsogt Dungubat; Hiroyuki Kusano; Dariimaa Ganbat; Yasuhiko Tomita; Sarandelger Odgerel; Toshio Fukusato
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.